Yourgene Health PLC
LSE:YGEN
Yourgene Health PLC
Yourgene Health Plc engages in the development and commercialization of genomic services and technologies. The principal activity of the Company is that of a molecular diagnostics business for research into, and the development and commercialization of gene analysis techniques for prenatal screening and other clinical applications in the early detection, monitoring and treatment of disease. The firm operates through two segments. The Genomic Technologies segment provides the in vitro diagnostic products, software and instrumentation manufactured by the Company and distributed globally through its direct and indirect sales channels. The Genomic Services segment operates testing laboratories in Taiwan and the United Kingdom and provides services to clinicians, third party clinical service providers and contract research organizations. These services require similar technical, commercial and managerial competences in the two host countries, and sometimes consume the output from the Genomic Technologies segment.
Yourgene Health Plc engages in the development and commercialization of genomic services and technologies. The principal activity of the Company is that of a molecular diagnostics business for research into, and the development and commercialization of gene analysis techniques for prenatal screening and other clinical applications in the early detection, monitoring and treatment of disease. The firm operates through two segments. The Genomic Technologies segment provides the in vitro diagnostic products, software and instrumentation manufactured by the Company and distributed globally through its direct and indirect sales channels. The Genomic Services segment operates testing laboratories in Taiwan and the United Kingdom and provides services to clinicians, third party clinical service providers and contract research organizations. These services require similar technical, commercial and managerial competences in the two host countries, and sometimes consume the output from the Genomic Technologies segment.
